Expert review: an update in current and developing intravesical therapies for non-muscle-invasive bladder cancer. Issue 11 (November 2013)

• Record Type: Journal Article
• Authors: van Lingen, Anna V; Arends, Tom JH; Witjes, J Alfred
• Is Part Of: Expert review of anticancer therapy. Volume 13:Issue 11(2013)
• Page Start: 1257
• Page End: 1268
• Publication Date: 2013-11
• Subjects: Bacillus Calmette–Guerin -- BCG failure -- chemotherapy -- early cystectomy -- immunotherapy -- intravesical therapy -- non-muscle-invasive bladder carcinoma -- transurethral resection of bladder tumor -- urothelial carcinoma; Cancer -- Treatment -- Periodicals; 616.99406
• DOI: 10.1586/14737140.2013.852474
• Languages: English
• ISSNs: 1473-7140

Abstract

Non-muscle-invasive bladder cancer is a highly prevalent disease and recurrences, after initial therapy, are common. Consequently, the healthcare costs for non-muscle-invasive bladder cancer are high. Despite a primary adequate response to adjuvant intravesical treatment, many patients suffer from recurrences, and some even from progression. To date, cystectomy remains the only option for those non-responding patients with high risk of recurrence and progression. Mainly because outcome after progression, in this group, is poor. Therefore, new intravesical therapies are needed. Moreover, new accurate and individual parameters, to distinguish responder from non-responders, will provide additional benefit in clinical decision-making. In this review, current diagnostics and therapies will be discussed. In addition, we will elucidate developing therapies in non-muscle-invasive bladder cancer.